Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 19/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7556017 | 0.91 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL5335179 | 0.88 | P2RX7 (0.55) | P2RX7 | |
| SCHEMBL14272604 | 0.88 | P2RX7 (0.55) | P2RX7 | |
| SCHEMBL7082380 | 0.87 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL7077648 | 0.87 | P2RX7 (0.66) | P2RX7 | |
| SCHEMBL4129931 | 0.86 | P2RX7 (0.71) | P2RX7 | |
| SCHEMBL7077870 | 0.85 | P2RX7 (0.54) | P2RX7 | |
| SCHEMBL6446984 | 0.85 | P2RX7 (0.52) | P2RX7 | |
| SCHEMBL5143075 | 0.85 | P2RX7 (0.72) | P2RX7 | |
| SCHEMBL7082054 | 0.85 | P2RX7 (0.78) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059497-A1 | PROCESS FOR PREPARING N-METHYLADAMANTYL DERIVATIVES BY A PALLADIUM CATALYSED COUPLING REACTION FOLLOWED BY REDUCTIVE AMINATION | AstraZeneca AB (SE) | 2009-05-20 | — | — | EP | claimed |
| WO-2008030160-A1 | PROCESS FOR PREPARING N-METHYLADAMANTYL DERIVATIVES BY A PALLADIUM CATALYSED COUPLING REACTION FOLLOWED BY REDUCTIVE AMINATION | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | WO | claimed |
| US-20030013704-A1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| EP-1242364-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044170-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013704-A1 | Adamantane derivatives | ADRA2C, CHRNA2, ADRA1D | P2RX7 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.